Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital Markets nudges up target price on Sainsbury's

(Sharecast News) - Analysts at RBC Capital Markets nudged up their target price on supermarket chain Sainsbury's from 300.0p to 305.0p on Friday after hosting an investor call with the group a day earlier. RBC Capital Markets said it had come away from Thursday's investor call "encouraged" by Sainsbury's momentum, particularly in food, noting that the company's food-focused approach was "seeing traction with consumers", and that it expects continued momentum to be supported by ongoing innovation and also by a reallocation of general merchandise space to good.

The Canadian bank also said Sainsbury's valuation looks undemanding relative to key peers, leading it to reiterate its 'outperform' rating on the stock.

"Following SBRY's Q1 trading update earlier this week, we have nudged up our FY26-27 EPS forecasts. Our PT moves to 305p from 300p. SBRY is currently trading at c.13x CY25e P/E, a little ahead of ts historic average but at a wider than average discount to TSCO (c.2x vs c.1x historically), despite a similar MSD % CY24-27 EPS CAGR and a higher all-in yield this year (>10%), from a combination of ordinary dividends, special dividends and a share buyback," added RBC.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.